Pharma Focus Asia

RNA Therapeutics


Guillermo Tramontin and Cecilia Piergentili


While traditionally small molecules medicines and antibodies target specific proteins, RNA therapeutics target RNA molecules involved in disease processes, allowing for more precise and effective treatment. 

A key advantage of RNA therapeutics is the ability to target previously "undruggable" targets, such as transcription factors and non-coding RNAs, which are often involved in complex disease pathways. 

Additionally, RNA-based treatments can be designed to be highly selective and specific, reducing the risk of off-target effects and improving safety profiles (Winkler, 2021; Zhu et al. 2022). 

Development of these innovative therapies has been facilitated by technological advances and an understanding of RNA biology, including synthesizing and delivery of RNA molecules to specific tissues and cells in the body. 

Download '.pdf' Format of the whitepaper.

Download Whitepapers
Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024